Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study-Reference-Cited by-同舟云学术

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study

Published:2022-07 Issue:3 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Norell Puck N.¹,Ivarsson Bodil²,Selin Maria³,Kjellström Barbro⁴⁵^ORCID

Affiliation:

1. Department of Medicine Karolinska Institutet Stockholm Sweden

2. Department of Clinical Sciences, Lund University Lund Cardiothoracic Surgery, and Medicine Services University Trust, Region Skåne Lund Sweden

3. Heart Centre Cardiology, Umeå University Hospital Umeå Sweden

4. Department of Clinical Sciences Lund, Clinical Physiology and Skåne University Hospital Lund University Lund Sweden

5. Cardiology Unit, Department of Medicine Karolinska Institutet Stockholm Sweden

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12114

Reference26 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

3. Selexipag for the Treatment of Pulmonary Arterial Hypertension

4. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

5. Risk stratification and medical therapy of pulmonary arterial hypertension

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Management of Mild Pulmonary Hypertension in Clinical Practice;Annals of the American Thoracic Society;2024-08